Biopharmaceutical company Takeda has announced the launch of its Cdpath program, which uses a blood test to predict someone’s risk for developing Crohn’s disease within the next three years, according to a Sept. 14 press release sent to Becker’s.
Takeda launches prognostic Crohn’s disease blood test
